Last reviewed · How we verify
Diuretic
Diuretic, marketed by Reprieve Cardiovascular, Inc., is positioned in the bloating relief segment. The drug's key strength lies in its mechanism of action, which effectively addresses bloating, a common and often under-treated condition. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Diuretic |
|---|---|
| Sponsor | Reprieve Cardiovascular, Inc |
| Drug class | Calculi Dissolution Agent [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Bloating relief
- Swelling relief
- Joint stiffness relief
- Weight gain relief
- Fatigue relief
- Headache relief
Common side effects
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Heart Failure (NA)
- Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure (NA)
- Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study (PHASE4)
- ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure (NA)
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- Evaluating the Effects of Nitroglycerin on Heart Function and Urinary Output in Patients With Acute Heart Failure (PHASE4)
- Hemodynamic Resuscitation Guided by Non-Invasive Mean Systemic Filling Pressure to Prevent Acute Kidney Injury in Septic Shock (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |